Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84221 | 0.84 | TAAR1 (0.43) | TAAR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL8415993 | 0.83 | TAAR1 (0.40) | TAAR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL7580846 | 0.83 | TAAR1 (0.40) | TAAR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL83319 | 0.81 | NPC1 (0.46) | TAAR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL8164187 | 0.81 | MAPT (0.46) | TAAR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL6967654 | 0.81 | TAAR1 (0.44) | TAAR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL8165766 | 0.81 | MAPT (0.46) | TAAR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL8816195 | 0.81 | NPC1 (0.47) | TAAR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL82386 | 0.81 | NPC1 (0.47) | TAAR1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL7583557 | 0.80 | NPC1 (0.39) | TAAR1NPC1RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8128943-B2 | Use of oxazole derivatives for controlling fish parasites | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | claimed |
| US-20100303865-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | claimed |
| EP-1931204-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | Novartis AG (CH) | 2008-06-18 | — | — | EP | claimed |
| WO-2007025694-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | claimed |
| US-8128943-B2 | Use of oxazole derivatives for controlling fish parasites | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100303865-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| EP-1931204-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007025694-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| EP-1165527-A1 | PESTICIDAL ENANTIOMER-PURE 2,4-DISUBSTITUTED OXAZOLINES | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058291-A1 | PESTICIDAL ENANTIOMER-PURE 2,4-DISUBSTITUTED OXAZOLINES | NOVARTIS AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303865-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | OXA1L, NPY5R, ZFX | TAAR1 2692/4885NPC1 3540/4885RAB9A 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.